Cagrilintide Dosage Guide
Complete guide to Cagrilintide dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
300 mcg – 4.5 mg
Frequency
Once per week
Route
subcutaneous
Cycle Length
26–68 weeks
Reconstitution
Vial Size
5 mg
BAC Water
2.0 ml
Concentration
2,500 mcg/ml
Detailed Dosage Information
Clinical trials
2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema).
Optimal dosing still being determined.
Administration Method
Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.
Research Use Only: All dosage ranges and calculations are derived from published research literature and are provided for educational purposes. These are not prescriptions or medical recommendations. Consult a healthcare professional before any use.
Concentration: 2.5 mg/ml
Volume to inject: 0.960 ml
Syringe units: 96.0 units
U-100 insulin syringe (100 units = 1 ml). Verify dose with a clinician before injecting.
Pre-filled with Cagrilintide defaults. Adjust values as needed.
Side Effects to Monitor
Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.
Safety Considerations & Risks
Investigational compound - full safety profile being established. Expected to carry similar warnings to approved amylin analog pramlintide.